http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105213425-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7390d83907b6a5043c4aa685e25c77ff |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549 |
| filingDate | 2015-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff6d1bc516ea4fa4e5d94f199da2ee39 |
| publicationDate | 2016-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105213425-A |
| titleOfInvention | One treats hypertensive compound recipe reserpine oral cavity disintegration tablet and preparation method thereof |
| abstract | The invention belongs to pharmaceutical field, be specifically related to one and treated hypertensive compound recipe reserpine drug port cavity disintegrating tablet and preparation method thereof.Described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, vitamin B1? 1 part, vitamin B6? 1 part, stabilizing agent fumaric acid 2-10 part and other pharmaceutic adjuvants.Experimental result shows that this drug port cavity disintegrating tablet onset time is short, and duration of efficacy is long, is convenient to patient's long-term treatment, improve drug safety, formulation and technology robustness is strong simultaneously, not by the impact of ambient temperature and humidity, significantly reduces the stability of preparation differences between batches and raising sample. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108096203-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105920009-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108096203-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109745337-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106619707-A |
| priorityDate | 2015-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 114.